Urological Cancer Drugs Market Report

Japan Urological Cancer Drugs Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major Region

  • POSTDATE：Sep 14, 2019
  • PAGES：205
  • REPORT CODE：GMM223901
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the Japan Urological Cancer Drugs market. It also provides a detailed overview of the market of different regions across Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, Shikoku, Kyushu. The report deep analyzes type and application in Japan Urological Cancer Drugs market. Detailed analysis of key players, along with key growth strategies adopted by Urological Cancer Drugs industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.


    By Player:

    • AstraZeneca

    • Abbott Laboratories

    • Ipsen

    • Bristol-Myers Squibb

    • GlaxoSmithKline

    • Indevus Pharmaceuticals Inc

    • Ferring Pharmaceuticals

    • Roche Healthcare

    • Pfizer

    • Sanofi S.A.

    • Celgene Corporation

    • Dendreon Corporation

    • Astellas

    • Sanofi SA

    • Novartis

    • Johnson & Johnson


    By Type:

    • Xofigo (Radium Ra 223 Dichloride)

    • Jevtana (Cabazitaxel)

    • Inlyta (Axitinib)

    • Votrient (Pazopanib Hydrochloride)

    • Sutent (Sunitinib Malate)

    • Zytiga (Abiraterone Acetate)

    • Xtandi (Enzalutamide)

    • Opdivo (Nivolumab)

    • Provenge (Sipuleucel-T)


    By End-User:

    • Prostate Cancer

    • Bladder Cancer

    • Kidney Cancer

    • Testicular Cancer


    By Region:

    • Hokkaido

    • Tohoku

    • Kanto

    • Chubu

    • Kinki

    • Chugoku

    • Shikoku

    • Kyushu

  • 1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Urological Cancer Drugs Market

    • 1.3 Market Segment by Type

      • 1.3.1 Japan Urological Cancer Drugs Market Size and Growth Rate of Xofigo (Radium Ra 223 Dichloride) from 2014 to 2026

      • 1.3.2 Japan Urological Cancer Drugs Market Size and Growth Rate of Jevtana (Cabazitaxel) from 2014 to 2026

      • 1.3.3 Japan Urological Cancer Drugs Market Size and Growth Rate of Inlyta (Axitinib) from 2014 to 2026

      • 1.3.4 Japan Urological Cancer Drugs Market Size and Growth Rate of Votrient (Pazopanib Hydrochloride) from 2014 to 2026

      • 1.3.5 Japan Urological Cancer Drugs Market Size and Growth Rate of Sutent (Sunitinib Malate) from 2014 to 2026

      • 1.3.6 Japan Urological Cancer Drugs Market Size and Growth Rate of Zytiga (Abiraterone Acetate) from 2014 to 2026

      • 1.3.7 Japan Urological Cancer Drugs Market Size and Growth Rate of Xtandi (Enzalutamide) from 2014 to 2026

      • 1.3.8 Japan Urological Cancer Drugs Market Size and Growth Rate of Opdivo (Nivolumab) from 2014 to 2026

      • 1.3.9 Japan Urological Cancer Drugs Market Size and Growth Rate of Provenge (Sipuleucel-T) from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Japan Urological Cancer Drugs Market Size and Growth Rate of Prostate Cancer from 2014 to 2026

      • 1.4.2 Japan Urological Cancer Drugs Market Size and Growth Rate of Bladder Cancer from 2014 to 2026

      • 1.4.3 Japan Urological Cancer Drugs Market Size and Growth Rate of Kidney Cancer from 2014 to 2026

      • 1.4.4 Japan Urological Cancer Drugs Market Size and Growth Rate of Testicular Cancer from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Hokkaido Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Tohoku Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Kanto Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Chubu Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Kinki Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Chugoku Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Shikoku Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Kyushu Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026


    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants


    3 Segmentation of Urological Cancer Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Urological Cancer Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Xofigo (Radium Ra 223 Dichloride)

      • 3.4.2 Market Size and Growth Rate of Jevtana (Cabazitaxel)

      • 3.4.3 Market Size and Growth Rate of Inlyta (Axitinib)

      • 3.4.4 Market Size and Growth Rate of Votrient (Pazopanib Hydrochloride)

      • 3.4.5 Market Size and Growth Rate of Sutent (Sunitinib Malate)

      • 3.4.6 Market Size and Growth Rate of Zytiga (Abiraterone Acetate)

      • 3.4.7 Market Size and Growth Rate of Xtandi (Enzalutamide)

      • 3.4.8 Market Size and Growth Rate of Opdivo (Nivolumab)

      • 3.4.9 Market Size and Growth Rate of Provenge (Sipuleucel-T)

    4 Segmentation of Urological Cancer Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Urological Cancer Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Urological Cancer Drugs in Prostate Cancer

      • 4.4.2 Market Size and Growth Rate of Urological Cancer Drugs in Bladder Cancer

      • 4.4.3 Market Size and Growth Rate of Urological Cancer Drugs in Kidney Cancer

      • 4.4.4 Market Size and Growth Rate of Urological Cancer Drugs in Testicular Cancer


    5 Market Analysis by Regions

    • 5.1 Japan Urological Cancer Drugs Production Analysis by Regions

    • 5.2 Japan Urological Cancer Drugs Consumption Analysis by Regions


    6 Hokkaido Urological Cancer Drugs Landscape Analysis

    • 6.1 Hokkaido Urological Cancer Drugs Landscape Analysis by Major Types

    • 6.2 Hokkaido Urological Cancer Drugs Landscape Analysis by Major End-Users


    7 Tohoku Urological Cancer Drugs Landscape Analysis

    • 7.1 Tohoku Urological Cancer Drugs Landscape Analysis by Major Types

    • 7.2 Tohoku Urological Cancer Drugs Landscape Analysis by Major End-Users


    8 Kanto Urological Cancer Drugs Landscape Analysis

    • 8.1 Kanto Urological Cancer Drugs Landscape Analysis by Major Types

    • 8.2 Kanto Urological Cancer Drugs Landscape Analysis by Major End-Users


    9 Chubu Urological Cancer Drugs Landscape Analysis

    • 9.1 Chubu Urological Cancer Drugs Landscape Analysis by Major Types

    • 9.2 Chubu Urological Cancer Drugs Landscape Analysis by Major End-Users


    10 Kinki Urological Cancer Drugs Landscape Analysis

    • 10.1 Kinki Urological Cancer Drugs Landscape Analysis by Major Types

    • 10.2 Kinki Urological Cancer Drugs Landscape Analysis by Major End-Users


    11 Chugoku Urological Cancer Drugs Landscape Analysis

    • 11.1 Chugoku Urological Cancer Drugs Landscape Analysis by Major Types

    • 11.2 Chugoku Urological Cancer Drugs Landscape Analysis by Major End-Users


    12 Shikoku Urological Cancer Drugs Landscape Analysis

    • 12.1 Shikoku Urological Cancer Drugs Landscape Analysis by Major Types

    • 12.2 Shikoku Urological Cancer Drugs Landscape Analysis by Major End-Users


    13 Kyushu Urological Cancer Drugs Landscape Analysis

    • 13.1 Kyushu Urological Cancer Drugs Landscape Analysis by Major Types

    • 13.2 Kyushu Urological Cancer Drugs Landscape Analysis by Major End-Users


    14 Major Players Profiles

    • 14.1 AstraZeneca

      • 14.1.1 AstraZeneca Company Profile and Recent Development

      • 14.1.2 Market Performance

      • 14.1.3 Product and Service Introduction

    • 14.2 Abbott Laboratories

      • 14.2.1 Abbott Laboratories Company Profile and Recent Development

      • 14.2.2 Market Performance

      • 14.2.3 Product and Service Introduction

    • 14.3 Ipsen

      • 14.3.1 Ipsen Company Profile and Recent Development

      • 14.3.2 Market Performance

      • 14.3.3 Product and Service Introduction

    • 14.4 Bristol-Myers Squibb

      • 14.4.1 Bristol-Myers Squibb Company Profile and Recent Development

      • 14.4.2 Market Performance

      • 14.4.3 Product and Service Introduction

    • 14.5 GlaxoSmithKline

      • 14.5.1 GlaxoSmithKline Company Profile and Recent Development

      • 14.5.2 Market Performance

      • 14.5.3 Product and Service Introduction

    • 14.6 Indevus Pharmaceuticals Inc

      • 14.6.1 Indevus Pharmaceuticals Inc Company Profile and Recent Development

      • 14.6.2 Market Performance

      • 14.6.3 Product and Service Introduction

    • 14.7 Ferring Pharmaceuticals

      • 14.7.1 Ferring Pharmaceuticals Company Profile and Recent Development

      • 14.7.2 Market Performance

      • 14.7.3 Product and Service Introduction

    • 14.8 Roche Healthcare

      • 14.8.1 Roche Healthcare Company Profile and Recent Development

      • 14.8.2 Market Performance

      • 14.8.3 Product and Service Introduction

    • 14.9 Pfizer

      • 14.9.1 Pfizer Company Profile and Recent Development

      • 14.9.2 Market Performance

      • 14.9.3 Product and Service Introduction

    • 14.10 Sanofi S.A.

      • 14.10.1 Sanofi S.A. Company Profile and Recent Development

      • 14.10.2 Market Performance

      • 14.10.3 Product and Service Introduction

    • 14.11 Celgene Corporation

      • 14.11.1 Celgene Corporation Company Profile and Recent Development

      • 14.11.2 Market Performance

      • 14.11.3 Product and Service Introduction

    • 14.12 Dendreon Corporation

      • 14.12.1 Dendreon Corporation Company Profile and Recent Development

      • 14.12.2 Market Performance

      • 14.12.3 Product and Service Introduction

    • 14.13 Astellas

      • 14.13.1 Astellas Company Profile and Recent Development

      • 14.13.2 Market Performance

      • 14.13.3 Product and Service Introduction

    • 14.14 Sanofi SA

      • 14.14.1 Sanofi SA Company Profile and Recent Development

      • 14.14.2 Market Performance

      • 14.14.3 Product and Service Introduction

    • 14.15 Novartis

      • 14.15.1 Novartis Company Profile and Recent Development

      • 14.15.2 Market Performance

      • 14.15.3 Product and Service Introduction

    • 14.16 Johnson & Johnson

      • 14.16.1 Johnson & Johnson Company Profile and Recent Development

      • 14.16.2 Market Performance

      • 14.16.3 Product and Service Introduction

     

    The List of Tables and Figures (Totals 110 Figures and 123 Tables)

     

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Xofigo (Radium Ra 223 Dichloride) from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Jevtana (Cabazitaxel) from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Inlyta (Axitinib) from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Votrient (Pazopanib Hydrochloride) from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Sutent (Sunitinib Malate) from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Zytiga (Abiraterone Acetate) from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Xtandi (Enzalutamide) from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Opdivo (Nivolumab) from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Provenge (Sipuleucel-T) from 2014 to 2026

    • Figure Market Share by Type in 2014

    • Figure Market Share by Type in 2018

    • Figure Market Share by Type in 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Prostate Cancer from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Bladder Cancer from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Kidney Cancer from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Testicular Cancer from 2014 to 2026

    • Figure Market Share by End-User in 2014

    • Figure Market Share by End-User in 2018

    • Figure Market Share by End-User in 2026

    • Figure Hokkaido Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Tohoku Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kanto Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chubu Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kinki Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chugoku Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Shikoku Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kyushu Urological Cancer Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Urological Cancer Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2018

    • Figure Market Share of TOP 5 Players in 2018

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Urological Cancer Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Urological Cancer Drugs by Different Types from 2014 to 2026

    • Table Consumption Share of Urological Cancer Drugs by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Xofigo (Radium Ra 223 Dichloride)

    • Figure Market Size and Growth Rate of Jevtana (Cabazitaxel)

    • Figure Market Size and Growth Rate of Inlyta (Axitinib)

    • Figure Market Size and Growth Rate of Votrient (Pazopanib Hydrochloride)

    • Figure Market Size and Growth Rate of Sutent (Sunitinib Malate)

    • Figure Market Size and Growth Rate of Zytiga (Abiraterone Acetate)

    • Figure Market Size and Growth Rate of Xtandi (Enzalutamide)

    • Figure Market Size and Growth Rate of Opdivo (Nivolumab)

    • Figure Market Size and Growth Rate of Provenge (Sipuleucel-T)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Urological Cancer Drugs by Different End-Users from 2014 to 2026

    • Table Consumption Share of Urological Cancer Drugs by Different End-Users from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Prostate Cancer from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Bladder Cancer from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Kidney Cancer from 2014 to 2026

    • Figure Japan Urological Cancer Drugs Market Size and Growth Rate of Testicular Cancer from 2014 to 2026

    • Table Japan Urological Cancer Drugs Production by Regions

    • Table Japan Urological Cancer Drugs Production Share by Regions

    • Figure Japan Urological Cancer Drugs Production Share by Regions in 2014

    • Figure Japan Urological Cancer Drugs Production Share by Regions in 2018

    • Figure Japan Urological Cancer Drugs Production Share by Regions in 2026

    • Table Japan Urological Cancer Drugs Consumption by Regions

    • Table Japan Urological Cancer Drugs Consumption Share by Regions

    • Figure Japan Urological Cancer Drugs Consumption Share by Regions in 2014

    • Figure Japan Urological Cancer Drugs Consumption Share by Regions in 2018

    • Figure Japan Urological Cancer Drugs Consumption Share by Regions in 2026

    • Table Hokkaido Urological Cancer Drugs Consumption by Types from 2014 to 2026

    • Table Hokkaido Urological Cancer Drugs Consumption Share by Types from 2014 to 2026

    • Figure Hokkaido Urological Cancer Drugs Consumption Share by Types in 2014

    • Figure Hokkaido Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Hokkaido Urological Cancer Drugs Consumption Share by Types in 2026

    • Table Hokkaido Urological Cancer Drugs Consumption by End-Users from 2014 to 2026

    • Table Hokkaido Urological Cancer Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Hokkaido Urological Cancer Drugs Consumption Share by End-Users in 2014

    • Figure Hokkaido Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Hokkaido Urological Cancer Drugs Consumption Share by End-Users in 2026

    • Table Tohoku Urological Cancer Drugs Consumption by Types from 2014 to 2026

    • Table Tohoku Urological Cancer Drugs Consumption Share by Types from 2014 to 2026

    • Figure Tohoku Urological Cancer Drugs Consumption Share by Types in 2014

    • Figure Tohoku Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Tohoku Urological Cancer Drugs Consumption Share by Types in 2026

    • Table Tohoku Urological Cancer Drugs Consumption by End-Users from 2014 to 2026

    • Table Tohoku Urological Cancer Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Tohoku Urological Cancer Drugs Consumption Share by End-Users in 2014

    • Figure Tohoku Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Tohoku Urological Cancer Drugs Consumption Share by End-Users in 2026

    • Table Kanto Urological Cancer Drugs Consumption by Types from 2014 to 2026

    • Table Kanto Urological Cancer Drugs Consumption Share by Types from 2014 to 2026

    • Figure Kanto Urological Cancer Drugs Consumption Share by Types in 2014

    • Figure Kanto Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Kanto Urological Cancer Drugs Consumption Share by Types in 2026

    • Table Kanto Urological Cancer Drugs Consumption by End-Users from 2014 to 2026

    • Table Kanto Urological Cancer Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Kanto Urological Cancer Drugs Consumption Share by End-Users in 2014

    • Figure Kanto Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Kanto Urological Cancer Drugs Consumption Share by End-Users in 2026

    • Table Chubu Urological Cancer Drugs Consumption by Types from 2014 to 2026

    • Table Chubu Urological Cancer Drugs Consumption Share by Types from 2014 to 2026

    • Figure Chubu Urological Cancer Drugs Consumption Share by Types in 2014

    • Figure Chubu Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Chubu Urological Cancer Drugs Consumption Share by Types in 2026

    • Table Chubu Urological Cancer Drugs Consumption by End-Users from 2014 to 2026

    • Table Chubu Urological Cancer Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Chubu Urological Cancer Drugs Consumption Share by End-Users in 2014

    • Figure Chubu Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Chubu Urological Cancer Drugs Consumption Share by End-Users in 2026

    • Table Kinki Urological Cancer Drugs Consumption by Types from 2014 to 2026

    • Table Kinki Urological Cancer Drugs Consumption Share by Types from 2014 to 2026

    • Figure Kinki Urological Cancer Drugs Consumption Share by Types in 2014

    • Figure Kinki Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Kinki Urological Cancer Drugs Consumption Share by Types in 2026

    • Table Kinki Urological Cancer Drugs Consumption by End-Users from 2014 to 2026

    • Table Kinki Urological Cancer Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Kinki Urological Cancer Drugs Consumption Share by End-Users in 2014

    • Figure Kinki Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Kinki Urological Cancer Drugs Consumption Share by End-Users in 2026

    • Table Chugoku Urological Cancer Drugs Consumption by Types from 2014 to 2026

    • Table Chugoku Urological Cancer Drugs Consumption Share by Types from 2014 to 2026

    • Figure Chugoku Urological Cancer Drugs Consumption Share by Types in 2014

    • Figure Chugoku Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Chugoku Urological Cancer Drugs Consumption Share by Types in 2026

    • Table Chugoku Urological Cancer Drugs Consumption by End-Users from 2014 to 2026

    • Table Chugoku Urological Cancer Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Chugoku Urological Cancer Drugs Consumption Share by End-Users in 2014

    • Figure Chugoku Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Chugoku Urological Cancer Drugs Consumption Share by End-Users in 2026

    • Table Shikoku Urological Cancer Drugs Consumption by Types from 2014 to 2026

    • Table Shikoku Urological Cancer Drugs Consumption Share by Types from 2014 to 2026

    • Figure Shikoku Urological Cancer Drugs Consumption Share by Types in 2014

    • Figure Shikoku Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Shikoku Urological Cancer Drugs Consumption Share by Types in 2026

    • Table Shikoku Urological Cancer Drugs Consumption by End-Users from 2014 to 2026

    • Table Shikoku Urological Cancer Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Shikoku Urological Cancer Drugs Consumption Share by End-Users in 2014

    • Figure Shikoku Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Shikoku Urological Cancer Drugs Consumption Share by End-Users in 2026

    • Table Kyushu Urological Cancer Drugs Consumption by Types from 2014 to 2026

    • Table Kyushu Urological Cancer Drugs Consumption Share by Types from 2014 to 2026

    • Figure Kyushu Urological Cancer Drugs Consumption Share by Types in 2014

    • Figure Kyushu Urological Cancer Drugs Consumption Share by Types in 2018

    • Figure Kyushu Urological Cancer Drugs Consumption Share by Types in 2026

    • Table Kyushu Urological Cancer Drugs Consumption by End-Users from 2014 to 2026

    • Table Kyushu Urological Cancer Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Kyushu Urological Cancer Drugs Consumption Share by End-Users in 2014

    • Figure Kyushu Urological Cancer Drugs Consumption Share by End-Users in 2018

    • Figure Kyushu Urological Cancer Drugs Consumption Share by End-Users in 2026

    • Table Company Profile and Development Status of AstraZeneca

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca

    • Figure Sales and Growth Rate Analysis of AstraZeneca

    • Figure Revenue and Market Share Analysis of AstraZeneca

    • Table Product and Service Introduction of AstraZeneca

    • Table Company Profile and Development Status of Abbott Laboratories

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Abbott Laboratories

    • Figure Sales and Growth Rate Analysis of Abbott Laboratories

    • Figure Revenue and Market Share Analysis of Abbott Laboratories

    • Table Product and Service Introduction of Abbott Laboratories

    • Table Company Profile and Development Status of Ipsen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ipsen

    • Figure Sales and Growth Rate Analysis of Ipsen

    • Figure Revenue and Market Share Analysis of Ipsen

    • Table Product and Service Introduction of Ipsen

    • Table Company Profile and Development Status of Bristol-Myers Squibb

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb

    • Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb

    • Figure Revenue and Market Share Analysis of Bristol-Myers Squibb

    • Table Product and Service Introduction of Bristol-Myers Squibb

    • Table Company Profile and Development Status of GlaxoSmithKline

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline

    • Table Product and Service Introduction of GlaxoSmithKline

    • Table Company Profile and Development Status of Indevus Pharmaceuticals Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Indevus Pharmaceuticals Inc

    • Figure Sales and Growth Rate Analysis of Indevus Pharmaceuticals Inc

    • Figure Revenue and Market Share Analysis of Indevus Pharmaceuticals Inc

    • Table Product and Service Introduction of Indevus Pharmaceuticals Inc

    • Table Company Profile and Development Status of Ferring Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ferring Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Ferring Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Ferring Pharmaceuticals

    • Table Product and Service Introduction of Ferring Pharmaceuticals

    • Table Company Profile and Development Status of Roche Healthcare

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche Healthcare

    • Figure Sales and Growth Rate Analysis of Roche Healthcare

    • Figure Revenue and Market Share Analysis of Roche Healthcare

    • Table Product and Service Introduction of Roche Healthcare

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Sanofi S.A.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi S.A.

    • Figure Sales and Growth Rate Analysis of Sanofi S.A.

    • Figure Revenue and Market Share Analysis of Sanofi S.A.

    • Table Product and Service Introduction of Sanofi S.A.

    • Table Company Profile and Development Status of Celgene Corporation

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Celgene Corporation

    • Figure Sales and Growth Rate Analysis of Celgene Corporation

    • Figure Revenue and Market Share Analysis of Celgene Corporation

    • Table Product and Service Introduction of Celgene Corporation

    • Table Company Profile and Development Status of Dendreon Corporation

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dendreon Corporation

    • Figure Sales and Growth Rate Analysis of Dendreon Corporation

    • Figure Revenue and Market Share Analysis of Dendreon Corporation

    • Table Product and Service Introduction of Dendreon Corporation

    • Table Company Profile and Development Status of Astellas

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astellas

    • Figure Sales and Growth Rate Analysis of Astellas

    • Figure Revenue and Market Share Analysis of Astellas

    • Table Product and Service Introduction of Astellas

    • Table Company Profile and Development Status of Sanofi SA

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi SA

    • Figure Sales and Growth Rate Analysis of Sanofi SA

    • Figure Revenue and Market Share Analysis of Sanofi SA

    • Table Product and Service Introduction of Sanofi SA

    • Table Company Profile and Development Status of Novartis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis

    • Figure Sales and Growth Rate Analysis of Novartis

    • Figure Revenue and Market Share Analysis of Novartis

    • Table Product and Service Introduction of Novartis

    • Table Company Profile and Development Status of Johnson & Johnson

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson

    • Figure Sales and Growth Rate Analysis of Johnson & Johnson

    • Figure Revenue and Market Share Analysis of Johnson & Johnson

    • Table Product and Service Introduction of Johnson & Johnson

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US